The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events | Zendy

Bradley D. Menz | Zendy; Jacinta Johnson | Zendy; Davina F. Gillard | Zendy; William Chong | Zendy; Michael Ward | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events

Author(s) -

Bradley D. Menz,

Jacinta Johnson,

Davina F. Gillard,

William Chong,

Michael Ward

Publication year - 2019

Publication title -

journal of pharmacy practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.407

H-Index - 28

eISSN - 1531-1937

pISSN - 0897-1900

DOI - 10.1177/0897190019872937

Subject(s) - medicine , nivolumab , adverse effect , ipilimumab , pharmacy , cancer , clinical trial , pharmacist , intensive care medicine , oncology , immunotherapy , family medicine

Immune checkpoint inhibitors (ICIs) are an emerging treatment in cancer therapy for prolonging life, minimizing symptoms, and selectively targeting cancer. Program death 1 (PD-1) inhibitors, such as nivolumab, fall within this class, enabling the patient's immune system to detect and destroy cancer. The introduction of ICIs is changing cancer therapy, with new drugs and new toxicities-an evolving area encountered by pharmacists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research